Ipsen Delivers Strong Growth and Expands Oncology Pipeline

We are proud to announce our robust performance across all therapeutic areas in the first nine months of 2025, underscoring our commitment to delivering transformative medicines to patients worldwide.

A Strong Year-to-Date Performance

Total sales rose by 12.1% at constant exchange rates. Growth was driven across all three therapeutic areas:

• Rare Disease: +101%
• Oncology: +6.6%
• Neuroscience: +9.5%

This performance has prompted an upgrade to our full-year 2025 guidance, now forecasting total sales growth of around 10% total sales growth* and a core operating margin of around 35%.

Strategic Expansion in Oncology

We also announced our intention to acquire ImCheck Therapeutics, a pioneering French biotech specializing in next-generation immuno-oncology. The acquisition centers on ICT01, a first-in-class monoclonal antibody targeting BTN3A1, currently in Phase I/II trials for first-line unfit acute myeloid leukemia (AML). Early data show unprecedented response rates, nearly double those of standard care.

This move reinforces Ipsen’s nearly 40-year legacy in Oncology, expanding our pipeline into hematology-oncology and addressing cancers with high unmet medical needs.

Looking Ahead

As we enter the final stretch of 2025, we remain focused on delivering innovative therapies to patients who need them most. Our continued growth and strategic investments reflect our belief that everyone deserves a life fully lived.

*At constant exchange rates